Silo Pharma, Inc. (NASDAQ: SILO)

Silo Pharma, Inc. is a developmental stage biopharmaceutical company focused on developing novel therapeutics that address underserved conditions including PTSD, stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. The company operates in the biopharmaceutical industry, specifically targeting mental health and neurological disorders through innovative drug formulations, including conventional drugs and psychedelic compounds. Silo Pharma's lead program, SPC-15, is an intranasal drug targeting PTSD and stress-induced anxiety disorders. Other key product candidates include SP-26, a ketamine-based implant for fibromyalgia and chronic pain relief, and preclinical programs SPC-14 for Alzheimer's disease and SPU-16 for CNS disorders, initially targeting multiple sclerosis.

Silo Pharma generates revenue through licensing agreements and milestone payments related to its product candidates. The company's primary products include SPC-15, SP-26, SPC-14, and SPU-16, each targeting specific underserved conditions within the mental health and neurological disorder markets. Silo Pharma's customer base includes academic institutions, research organizations, and potential pharmaceutical partners interested in licensing and developing its therapeutic candidates. The company collaborates with renowned educational institutions and advisors to acquire and develop intellectual property or technology rights for treating rare diseases and neurological disorders.

• SPC-15: This segment focuses on the development of an intranasal treatment for PTSD and stress-induced anxiety disorders. SPC-15 is designed as a novel serotonin 4 (5-HT4) receptor agonist, utilizing biomarkers for treatment. The product is administered via an intranasal formulation and is currently in the preclinical and formulation study phases. Silo Pharma has entered into exclusive license agreements with Columbia University and Medspray Pharma BV for the development and commercialization of SPC-15. The company aims to submit an Investigational New Drug (IND) application in 2025 and believes its patented intranasal nose-to-brain drug dispersion technology provides a competitive advantage by increasing brain drug concentration and ensuring a faster onset of therapeutic effects with optimized safety.

• SP-26: This segment involves the development of a ketamine-based injectable dissolvable polymer implant for treating chronic pain and fibromyalgia. SP-26 is designed for subcutaneous insertion and focuses on regulating dosage and time release to provide sustained relief from chronic pain. The product is currently in preclinical research, with initial animal studies evaluating the implant's dosage, time release, and absorption. Silo Pharma has filed a provisional patent application with the USPTO for SP-26 and intends to develop it following the Section 505(b)(2) regulatory pathway of the FDA rules. The company believes SP-26's implant design provides a compelling non-opioid alternative to traditional pain management, improving dosage control compared to intravenous delivery.

• SPC-14: This segment targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer's disease. SPC-14 was developed under a sponsored research agreement with Columbia University, and Silo Pharma has exclusive global rights to develop and commercialize the product. The company believes SPC-14 has shown efficacy against luteinizing hormone (LH) in attenuating learned helplessness, preservative behavior, and hyponeophagia. The global Alzheimer's therapeutics market is projected to exceed $30.8 billion by 2033, presenting a promising opportunity for SPC-14.

• SPU-16: This segment focuses on the development of a promising candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis. SPU-16 utilizes CNS-homing peptides to reduce toxicity while enhancing therapeutic payload delivery. Silo Pharma has entered into a Master License Agreement with the University of Maryland, Baltimore, granting exclusive worldwide rights to develop and commercialize SPU-16. The company believes SPU-16 provides a competitive advantage by using homing peptides to reduce toxicity while enhancing therapeutic payload delivery.

Silo Pharma operates in a competitive industry characterized by intense competition and a strong emphasis on proprietary product rights. The company faces potential competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions and governmental agencies. Key competitors include established players with significant financial, technical, and human resources, as well as smaller and earlier-stage companies that may prove to be significant competitors through collaborative arrangements. Silo Pharma's competitive advantages include its focus on merging traditional therapeutics with psychedelic research, exclusive license agreements with renowned educational institutions, and innovative drug formulations that target underserved conditions.

Silo Pharma's customer base includes academic institutions, research organizations, and potential pharmaceutical partners interested in licensing and developing its therapeutic candidates. The company collaborates with world-renowned educational institutions and advisors to acquire and develop intellectual property or technology rights for treating rare diseases and neurological disorders. Specific customers mentioned in the filing include Columbia University and the University of Maryland, Baltimore, with whom Silo Pharma has entered into license agreements and sponsored research agreements. The company's customer base also includes potential vendors, contract research organizations, and contract manufacturers that may be required to navigate the various preclinical, clinical, manufacturing, and commercial approval requirements of the governing regulatory agencies.